Moderna Financial Statements From 2010 to 2022

MRNA
 Stock
  

USD 186.84  7.34  3.78%   

Moderna financial statements provide useful quarterly and yearly information to potential Moderna investors about the company's current and past financial position, as well as its overall management performance and changes in financial position over time. Historical trend examination of various income statement and balance sheet accounts found on Moderna financial statements helps investors assess Moderna's valuation, profitability, and current liquidity needs.
We have found ninety-eight available fundamental ratios for Moderna, which can be analyzed and compared to other ratios and to its peers in the industry. Make sure you check all of Moderna last-minute market performance against the performance between 2010 and 2022 to make sure the company can sustain itself down the road.
The current year Net Income Per Employee is expected to grow to about 4.9 M. The current year Revenue Per Employee is expected to grow to about 7.4 M.
  
Check Moderna financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Moderna main balance sheet or income statement drivers, such as Direct Expenses of 2.8 B, Consolidated Income of 13.2 B or Cost of Revenue of 2.1 B, as well as many exotic indicators such as Long Term Debt to Equity of 0.0349, Calculated Tax Rate of 7.29 or PPandE Turnover of 25.92. Moderna financial statements analysis is a perfect complement when working with Moderna Valuation or Volatility modules. It can also supplement Moderna's financial leverage analysis and stock options assessment as well as various Moderna Technical models . Additionally, see the analysis of Moderna Correlation against competitors.

Moderna Revenues

19.93 Billion

Moderna Balance Sheet

Current ValueLast YearHistorical Average 10 Year Trend
Total Assets26.6 B24.7 B5.6 B
Increasing
Slightly volatile
Cash and Equivalents7.4 B6.8 B1.4 B
Increasing
Slightly volatile
Investments11.6 B10.7 B2.8 B
Increasing
Slightly volatile
Investments Current4.2 B3.9 B1.5 B
Increasing
Slightly volatile
Investments Non Current7.4 B6.9 B1.3 B
Increasing
Slightly volatile
Deferred Revenue7.4 B6.9 B1.7 B
Increasing
Slightly volatile
Property Plant and Equipment Net1.5 B1.4 B343.8 M
Increasing
Slightly volatile
Inventory1.2 B1.4 B242.1 M
Increasing
Slightly volatile
Tax Assets291.7 M293.4 M320.9 M
Decreasing
Slightly volatile
Trade and Non Trade Receivables3.4 B3.2 B624.4 M
Increasing
Slightly volatile
Trade and Non Trade Payables325.8 M302 M69.4 M
Increasing
Slightly volatile
Total Liabilities11.4 B10.5 B2.5 B
Increasing
Slightly volatile
Shareholders Equity15.3 B14.1 B2.4 B
Increasing
Slightly volatile
Accumulated Retained Earnings Deficit10.7 B10 B982.6 M
Increasing
Slightly volatile
Accumulated Other Comprehensive Income(24.6 M)(24 M)(3.8 M)
Decreasing
Slightly volatile
Current Assets17.3 B16.1 B3.9 B
Increasing
Slightly volatile
Assets Non Current9.3 B8.6 B1.7 B
Increasing
Slightly volatile
Current Liabilities9.8 B9.1 B1.9 B
Increasing
Slightly volatile
Liabilities Non Current1.5 B1.4 B532.7 M
Increasing
Slightly volatile
Tax Liabilities783.8 M788.4 M862.2 M
Decreasing
Slightly volatile
Total Debt760.7 M705 M149.4 M
Increasing
Slightly volatile
Debt Non Current760.7 M705 M149.4 M
Increasing
Slightly volatile
Shareholders Equity USD15.3 B14.1 B2.4 B
Increasing
Slightly volatile
Cash and Equivalents USD7.4 B6.8 B1.4 B
Increasing
Slightly volatile
Total Debt USD760.7 M705 M149.4 M
Increasing
Slightly volatile
Accounts Payable325.8 M302 M69.4 M
Increasing
Slightly volatile
Receivables3.5 B3.2 B638.7 M
Increasing
Slightly volatile
Inventories1.6 B1.4 B269.8 M
Increasing
Slightly volatile

Moderna Income Statement

Current ValueLast YearHistorical Average 10 Year Trend
Revenues19.9 B18.5 B3.1 B
Increasing
Slightly volatile
Cost of Revenue2.1 B2.6 B372.5 M
Increasing
Slightly volatile
Selling General and Administrative Expense611.8 M567 M156.8 M
Increasing
Slightly volatile
Research and Development Expense2.1 BB676.4 M
Increasing
Slightly volatile
Operating Expenses2.8 B2.6 B833.1 M
Increasing
Slightly volatile
Income Tax Expense1.2 B1.1 B173.9 M
Increasing
Slightly volatile
Consolidated Income13.2 B12.2 B1.7 B
Increasing
Slightly volatile
Net Income13.2 B12.2 B1.7 B
Increasing
Slightly volatile
Preferred Dividends Income Statement Impact19.1 M19.7 M15.6 M
Increasing
Slightly volatile
Net Income Common Stock13.2 B12.2 B1.7 B
Increasing
Slightly volatile
Weighted Average Shares339.6 M403 M155.8 M
Increasing
Slightly volatile
Weighted Average Shares Diluted357 M431 M159.3 M
Increasing
Slightly volatile
Earning Before Interest and Taxes EBIT14.3 B13.3 B1.9 B
Increasing
Slightly volatile
Revenues USD19.9 B18.5 B3.1 B
Increasing
Slightly volatile
Net Income Common Stock USD13.2 B12.2 B1.7 B
Increasing
Slightly volatile
Earning Before Interest and Taxes USD14.3 B13.3 B1.9 B
Increasing
Slightly volatile
Gross Profit17.1 B15.9 B2.7 B
Increasing
Slightly volatile
Operating Income14.3 B13.3 B1.9 B
Increasing
Slightly volatile
Direct Expenses2.8 B2.6 B425.2 M
Increasing
Slightly volatile

Moderna Cash Flow Statement

Current ValueLast YearHistorical Average 10 Year Trend
Net Cash Flow Investment Acquisitions and Disposals(8.5 B)(8.2 B)(1.7 B)
Decreasing
Slightly volatile
Net Cash Flow from Financing(896 M)(873 M)373.3 M
Decreasing
Stable
Issuance Repayment of Debt Securities (143.7 M)(140 M)(20.6 M)
Decreasing
Slightly volatile
Issuance Purchase of Equity Shares(752.3 M)(733 M)90 M
Increasing
Very volatile
Net Cash Flow from Investing(8.7 B)(8.5 B)(1.8 B)
Decreasing
Slightly volatile
Net Cash Flow from Operations14.7 B13.6 B2.3 B
Increasing
Slightly volatile
Net Cash Flow or Change in Cash and Cash Equivalents4.6 B4.2 B814.9 M
Increasing
Slightly volatile
Share Based Compensation119.9 M142 M63.4 M
Increasing
Slightly volatile
Depreciation Amortization and Accretion250.3 M232 M58.3 M
Increasing
Slightly volatile

Financial Ratios

Current ValueLast YearHistorical Average 10 Year Trend
Earnings per Basic Share32.7130.311.8343
Increasing
Slightly volatile
Earnings per Diluted Share30.5228.291.5109
Increasing
Slightly volatile
Earnings per Basic Share USD32.7130.311.8343
Increasing
Slightly volatile
Return on Average Equity1.511.4020.4821
Decreasing
Very volatile
Return on Average Assets0.710.656(0.085)
Increasing
Slightly volatile
Return on Invested Capital3.513.2510.2607
Increasing
Slightly volatile
Gross Margin0.860.8580.9777
Decreasing
Slightly volatile
Profit Margin0.710.661(2.0989)
Increasing
Stable
EBITDA Margin0.790.732(1.8526)
Increasing
Stable
Return on Sales0.770.719(2.0002)
Increasing
Stable
Asset Turnover1.070.9930.2839
Increasing
Slightly volatile
Enterprise Value over EBITDA7.87.233(13.8556)
Increasing
Very volatile
Enterprise Value over EBIT7.557.0(12.9575)
Increasing
Very volatile
Price to Earnings Ratio9.048.379(5.8665)
Decreasing
Stable
Sales per Share49.4545.8348.8401
Increasing
Slightly volatile
Price to Sales Ratio5.685.54119.3254
Increasing
Stable
Price to Book Value8.497.285.1229
Increasing
Slightly volatile
Debt to Equity Ratio0.80.744(0.6779)
Increasing
Slightly volatile
Current Ratio1.811.7615.4416
Decreasing
Slightly volatile
Free Cash Flow per Share35.7133.0924.9923
Increasing
Slightly volatile
Book Value per Share37.8735.0994.2285
Increasing
Slightly volatile
Tangible Assets Book Value per Share66.0461.21327.3556
Increasing
Slightly volatile
Total Assets Per Share66.0461.213425.3151
Increasing
Slightly volatile
Cash Flow Per Share36.4733.79655.788
Increasing
Slightly volatile
Return on Investment163151(6.9244)
Increasing
Slightly volatile
Operating Margin77.6671.9831(68.8647)
Increasing
Slightly volatile
Calculated Tax Rate7.297.348.0236
Decreasing
Slightly volatile
Receivables Turnover7.77.96769.6571
Decreasing
Slightly volatile
Inventory Turnover3.153.173.4636
Decreasing
Slightly volatile
PPandE Turnover25.9224.02125.3205
Increasing
Slightly volatile
Cash and Equivalents Turnover4.213.90022.0733
Increasing
Very volatile
Accounts Payable Turnover12411529.1087
Increasing
Slightly volatile
Accrued Expenses Turnover20.5319.02676.0634
Increasing
Slightly volatile
Long Term Debt to Equity0.03490.04230.0234
Increasing
Slightly volatile
Quick Ratio1.571.52865.349
Decreasing
Slightly volatile
Net Current Assets as percentage of Total Assets44.1728.144656.9076
Decreasing
Slightly volatile
Revenue to Assets0.810.74880.1923
Increasing
Slightly volatile

Moderna Valuation Data

Current ValueLast YearHistorical Average 10 Year Trend
Earnings before Tax14.3 B13.3 B1.9 B
Increasing
Slightly volatile
Earnings Before Interest Taxes and Depreciation Amortization EBITDA14.6 B13.5 B1.9 B
Increasing
Slightly volatile
Earnings Before Interest Taxes and Depreciation Amortization USD14.6 B13.5 B1.9 B
Increasing
Slightly volatile
Market Capitalization111.1 B103 B23.6 B
Increasing
Slightly volatile
Enterprise Value105.5 B97.8 B22.5 B
Increasing
Slightly volatile
Invested Capital10.1 B9.4 B2.4 B
Increasing
Slightly volatile
Average Equity9.4 B8.7 B1.4 B
Increasing
Slightly volatile
Average Assets20.1 B18.6 B4.3 B
Increasing
Slightly volatile
Invested Capital Average4.4 B4.1 B1.6 B
Increasing
Slightly volatile
Tangible Asset Value26.6 B24.7 B5.6 B
Increasing
Slightly volatile
Free Cash Flow14.4 B13.3 B2.2 B
Increasing
Slightly volatile
Working Capital7.5 B6.9 BB
Increasing
Slightly volatile
Revenue Per Employee7.4 M6.8 M1.3 M
Increasing
Slightly volatile
Net Income Per Employee4.9 M4.5 M367.1 K
Increasing
Slightly volatile

Moderna Fundamental Market Drivers

Forward Price Earnings18.57
Short Percent Of Float5.49%
Average Daily Volume Last 10 Day3.21M
Shares Short Prior Month14.76M
Average Daily Volume In Three Month5.56M
Date Short Interest15th of July 2022
Fifty Day Average148.52
Two Hundred Day Average193.09

Moderna Upcoming Events

Upcoming Quarterly Report24th of February 2022
Next Financial Report5th of May 2022
Next Fiscal Quarter End31st of December 2021
Next Fiscal Year End24th of February 2022
Last Quarter Report30th of September 2021
Last Financial Announcement31st of December 2020

About Moderna Financial Statements

There are typically three primary documents that fall into the category of financial statements. These documents include Moderna income statement, its balance sheet, and the statement of cash flows. Moderna investors use historical funamental indicators, such as Moderna's revenue or net income, to determine how well the company is positioned to perform in the future. Although Moderna investors may use each financial statement separately, they are all related. The changes in Moderna's assets and liabilities, for example, are also reflected in the revenues and expenses that we see on Moderna's income statement, which results in the company's gains or losses. Cash flows can provide more information regarding cash listed on a balance sheet, but not equivalent to net income shown on the income statement. We offer a historical overview of the basic patterns found on Moderna Financial Statements. Understanding these patterns can help to make the right decision on long term investment in Moderna. Please read more on our technical analysis and fundamental analysis pages.
Last ReportedProjected for 2022
Deferred Revenue6.9 B7.4 B
Cost of Revenue2.6 B2.1 B
Revenues18.5 B19.9 B
Revenue to Assets 0.75  0.81 
Revenue Per Employee6.8 M7.4 M
Moderna, Inc., a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, cardiovascular diseases, and auto-immune diseases in the United States, Europe, and internationally. Moderna, Inc. was founded in 2010 and is headquartered in Cambridge, Massachusetts. Moderna operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 3200 people.

Be your own money manager

Our tools can tell you how much better you can do entering a position in Moderna without increasing your portfolio risk or giving up expected return. As an individual investor, you need to find a reliable way to track all your investment portfolios. However, your requirements will often be based on how much of the process you decide to do yourself. In addition to allowing all investors analytical transparency into all their portfolios, our tools can evaluate.risk-adjusted returns of your individual positions relative to your overall portfolio.

Did you try this?

Run Portfolio File Import Now

   

Portfolio File Import

Quickly import all of your third-party portfolios from your local drive in csv format
All  Next Launch Module

Becoming a Better Investor with Macroaxis

Macroaxis puts the power of mathematics on your side. We analyze your portfolios and positions such as Moderna using complex mathematical models and algorithms, but make them easy to understand. There is no real person involved in your portfolio analysis. We perform a number of calculations to compute absolute and relative portfolio volatility, correlation between your assets, value at risk, expected return as well as over 100 different fundamental and technical indicators.

Build Optimal Portfolios

Align your risk with return expectations

Fix your portfolio
By capturing your risk tolerance and investment horizon Macroaxis technology of instant portfolio optimization will compute exactly how much risk is acceptable for your desired return expectations
Additionally, see the analysis of Moderna Correlation against competitors. Note that the Moderna information on this page should be used as a complementary analysis to other Moderna's statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try Theme Ratings module to determine theme ratings based on digital equity recommendations. Macroaxis theme ratings are based on combination of fundamental analysis and risk-adjusted market performance.

Complementary Tools for Moderna Stock analysis

When running Moderna price analysis, check to measure Moderna's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Moderna is operating at the current time. Most of Moderna's value examination focuses on studying past and present price action to predict the probability of Moderna's future price movements. You can analyze the entity against its peers and financial market as a whole to determine factors that move Moderna's price. Additionally, you may evaluate how the addition of Moderna to your portfolios can decrease your overall portfolio volatility.
Equity Forecasting
Use basic forecasting models to generate price predictions and determine price momentum
Go
Performance Analysis
Check effects of mean-variance optimization against your current asset allocation
Go
Portfolio Manager
State of the art Portfolio Manager to monitor and improve performance of your invested capital
Go
Competition Analyzer
Analyze and compare many basic indicators for a group of related or unrelated entities
Go
Portfolio Backtesting
Avoid under-diversification and over-optimization by backtesting your portfolios
Go
Companies Directory
Evaluate performance of over 100,000 Stocks, Funds, and ETFs against different fundamentals
Go
Is Moderna's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Moderna. If investors know Moderna will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Moderna listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth YOY
-0.19
Market Capitalization
73.1 B
Quarterly Revenue Growth YOY
0.091
Return On Assets
0.46
Return On Equity
1.14
The market value of Moderna is measured differently than its book value, which is the value of Moderna that is recorded on the company's balance sheet. Investors also form their own opinion of Moderna's value that differs from its market value or its book value, called intrinsic value, which is Moderna's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Moderna's market value can be influenced by many factors that don't directly affect Moderna's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Moderna's value and its price as these two are different measures arrived at by different means. Investors typically determine Moderna value by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Moderna's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.